Valley Heart & Vascular Institute - Clinical Trials
Share |

Acute Coronary Syndrome Trials/MI Trials

CIRT (Cardiovascular Inflammation Reduction Trial)

“Randomized, double-blind, placebo-controlled, event-driven trial of weekly low-dose methotrexate (LDM) in the prevention of cardiovascular events among stable coronary artery disease patients with type 2 diabetes or metabolic syndrome.”

Study Objective: The primary scientific aim of CIRT is to directly test the inflammatory hypothesis of atherothrombosis. Specifically, CIRT will evaluate whether LDM will reduce rates of myocardial infarction, stroke, or cardiovascular death among patients with a recent history of coronary artery disease and either type 2 diabetes or metabolic syndrome, conditions associated with an enhanced pro-inflammatory response.

Eligibility: A past history of heart attack or have past evidence of major blockages in more than one coronary artery found on a heart catheterization and have either type 2 diabetes or metabolic syndrome.

Principal Investigator: Janet Strain, MD


CLEAR

“Randomized, double-blind, placebo-controlled, parallel group, multi-center study to evaluate the efficacy and safety of bempedoic acid (ETC-1002), 180 mg/day, as add-on to ezetimibe therapy in patients with elevated LDL-C on low dose or less than low dose statins.”

Study Objective: To assess how well bempedoic acid works to reduce the amount of low-density lipoprotein cholesterol (LDL-C) in the body in patients who have elevated (high) levels of LDL-C and who are also taking ezetimibe.

Eligibility: Elevated (high) levels of LDL-C and are taking ezetimibe.

Principal Investigator: Janet Strain, MD

 
 
Copyright © 2017 Valley Health System. All rights reserved.